Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at Brookline Capital Markets raised their FY2026 EPS estimates for shares of Monopar Therapeutics in a report released on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver now expects that the company will post earnings per share of ($2.61) for the year, up from their prior forecast of ($2.70). The consensus estimate for Monopar Therapeutics' current full-year earnings is ($2.96) per share. Brookline Capital Markets also issued estimates for Monopar Therapeutics' Q4 2026 earnings at ($0.80) EPS.
Several other equities research analysts also recently issued reports on the stock. HC Wainwright reissued a "buy" rating on shares of Monopar Therapeutics in a research report on Thursday. Barclays restated an "overweight" rating and set a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a report on Friday, September 11th. Zacks Research cut shares of Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Monopar Therapeutics in a research note on Thursday, October 15th. Finally, Wall Street Zen lowered shares of Monopar Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, October 10th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Monopar Therapeutics has an average rating of "Moderate Buy" and an average price target of $123.12.
Read Our Latest Research Report on MNPR
Monopar Therapeutics Stock Down 0.0%
Shares of MNPR opened at $71.97 on Tuesday. Monopar Therapeutics has a twelve month low of $50.07 and a twelve month high of $124.82. The firm's 50 day moving average price is $81.68 and its two-hundred day moving average price is $77.43.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.72) EPS for the quarter, meeting analysts' consensus estimates of ($0.72).
Insider Buying and Selling at Monopar Therapeutics
In related news, Director Raymond Anderson sold 3,142 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $68.35, for a total transaction of $214,755.70. Following the completion of the transaction, the director owned 5,373 shares in the company, valued at approximately $367,244.55. This represents a 36.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of the firm's stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $88.00, for a total transaction of $2,556,928.00. Following the completion of the transaction, the chief executive officer directly owned 99,267 shares of the company's stock, valued at approximately $8,735,496. This trade represents a 22.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,920 shares of company stock valued at $4,527,913 over the last ninety days. 9.70% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Monopar Therapeutics
A number of large investors have recently modified their holdings of the business. Siren L.L.C. grew its stake in Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company's stock valued at $14,800,000 after purchasing an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC raised its stake in shares of Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company's stock worth $14,480,000 after purchasing an additional 30,370 shares in the last quarter. State Street Corp raised its stake in shares of Monopar Therapeutics by 24.1% during the 3rd quarter. State Street Corp now owns 229,771 shares of the company's stock worth $18,306,000 after purchasing an additional 44,669 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Monopar Therapeutics by 443.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 87,877 shares of the company's stock worth $7,001,000 after purchasing an additional 71,716 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Monopar Therapeutics by 21.2% in the 1st quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company's stock valued at $4,307,000 after buying an additional 13,761 shares during the last quarter. 1.83% of the stock is currently owned by institutional investors and hedge funds.
Monopar Therapeutics Company Profile
(
Get Free Report)
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.